Top

Published in:

01-04-2016 | News and Views

The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications

Authors: Ivo Meinhold-Heerlein, Christina Fotopoulou, Philipp Harter, Christian Kurzeder, Alexander Mustea, Pauline Wimberger, Steffen Hauptmann, Jalid Sehouli

Published in: Archives of Gynecology and Obstetrics | Issue 4/2016

Abstract

Introduction

Molecular pathological research has contributed to improving the knowledge of different subtypes of ovarian cancer. In parallel with the implementation of the new FIGO staging classification, the WHO classification was revised. The latter is mainly based on the histopathological findings and defines the actual type of tumor. It has, therefore, also an important impact on prognosis and therapy of the patient.

Materials and methods

The new WHO Classification of Ovarian Cancer published 2014 by Robert Kurman and co-authors is summarized. The major changes compared to the hitherto existing classification are presented.

Results

The new classification eliminates the previous focus of mesothelial origin of ovarian cancer. Instead, it features a discussion of tubal carcinogenesis of hereditary and some other high-grade serous carcinomas. The previously assumed pathogenesis pathway may be correct for some, but not for all, serous cancers. The new classification was established to classify ovarian cancer in a more consistent way. The earlier transitional cell type of ovarian cancer has been removed while seromucinous tumors have been added as a new entity. The role of some borderline tumors as one possible step in the progression from benign to invasive lesions is incorporated. The article summarizes the essential updates concerning serous, mucinous, seromucinous, endometrioid, clear-cell, and Brenner tumors.

Conclusion

The new WHO classification takes into account the recent findings on the origin, pathogenesis, and prognosis of different ovarian cancer subtypes. The tubal origin of hereditary and some non-hereditary high-grade serous cancers is mentioned in contrast to the hitherto theory of mesothelial origin of tumors. Seromucinous tumors represent a new entity.

Meinhold-Heerlein I, Hauptmann S (2014) The heterogeneity of ovarian cancer. Arch Gynecol Obstet 289:237–239CrossRefPubMed

Prat J, Oncology FCoG (2014) Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet Off Int Feder Gynaecol Obstet 124:1–5CrossRef

Zeppernick F, Meinhold-Heerlein I (2014) The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet 290:839–842CrossRefPubMed

Meinhold-Heerlein I, Fotopoulou C, Harter P et al (2015) Statement by the Kommission Ovar of the AGO: the new FIGO and WHO classifications of ovarian, fallopian tube and primary peritoneal cancer. Geburtshilfe Frauenheilkd 75:1021–1027CrossRefPubMedPubMedCentral

Kurman RJ, Carcangiu ML, Herrington CS et al (2014) WHO Classification of Tumours of Female Reproductive Organs. In WHO Classification of Tumours. 4. Aufl. Lyon: WHO Press

Pecorelli S, Benedet JL, Creasman WT et al (1999) FIGO staging of gynecologic cancer. 1994–1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 65:243–249

Shepherd JH (1989) Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 96:889–892CrossRefPubMed

Ledermann JA, Raja FA, Fotopoulou C et al (2013) Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology/ESMO 24 Suppl 6:vi24–32

10.

Wagner U, Harter P, Hilpert F et al (2013) S3-guideline on diagnostics, therapy and follow-up of malignant ovarian tumours: short version 1.0—AWMF registration number: 032/035OL, June 2013. Geburtshilfe Frauenheilkd 73:874–889CrossRefPubMedPubMedCentral

11.

Cancer NCCf (2011) Ovarian cancer: the recognition and initial management of ovarian cancer. In: http://www.nice.org.uk: National Collaborating Centre for Cancer, Cardiff, Wales

12.

Shih Ie M, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. The American journal of pathology 164:1511–1518

13.

Przybycin CG, Kurman RJ, Ronnett BM et al (2010) Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 34:1407–1416CrossRefPubMed

14.

Kurman RJ, Shih Ie M (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Hum Pathol 42:918–931CrossRefPubMedPubMedCentral

15.

Meinhold-Heerlein I, Bauerschlag D, Hilpert F et al (2005) Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24:1053–1065CrossRefPubMed

16.

Hauptmann S, du Bois A, Meinhold-Herlein I et al (2014) Histological grading of epithelial ovarian cancer. Review and recommendation. Der Pathologe 35:497–503

17.

Prat J (2012) New insights into ovarian cancer pathology. Ann Oncol Off J Eur Soc Med Oncol ESMO 23(Suppl 10):x111–x117CrossRef

18.

Hauptmann S (2015) Die neue WHO-Klassifikation des Ovarial-. Tuben- und primären Peritonealkarzinoms

19.

Chene G, Ouellet V, Rahimi K et al (2015) The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis. Int J Gynaecol Obstet Off Organ Int Feder Gynaecol Obstet 130:27–30CrossRef

20.

Wiegand KC, Shah SP, Al-Agha OM et al (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. New Engl J Med 363:1532–1543CrossRefPubMedPubMedCentral

21.

du Bois A, Ewald-Riegler N, de Gregorio N et al (2013) Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group. Eur J Cancer 49:1905–1914CrossRefPubMed

Title: The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications
Authors: Ivo Meinhold-Heerlein
Christina Fotopoulou
Philipp Harter
Christian Kurzeder
Alexander Mustea
Pauline Wimberger
Steffen Hauptmann
Jalid Sehouli
Publication date: 01-04-2016
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 4/2016
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-016-4035-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications

Abstract

Introduction

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2016

Propranolol and oxytocin versus oxytocin alone for induction and augmentation of labor: a meta-analysis of randomized trials

Metabolic syndrome in Greek women with polycystic ovary syndrome: prevalence, characteristics and associations with body mass index. A prospective controlled study

Primary retroperitoneal mucinous cystadenocarcinoma (PRMCa): a systematic review of the literature and meta-analysis

Association of −463G/A MPO gene polymorphism and risk of cervical intraepithelial neoplasia

Depression and anxiety in pregnant women with diabetes or mild hyperglycemia

Simultaneous detection of human papillomavirus integration and c-MYC gene amplification in cervical lesions: an emerging marker for the risk to progression